Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approves Tecentriq for NSCLC
Genentech news release; 2016 Oct 18
The FDA has approved Tecentriq (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC).
Indications: Tecentriq is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
Dosage and administration: Administer 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.
Efficacy and safety: Approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies, which showed that Tecentriq helped people in the overall study population live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy.
Side effects/risks: Most common adverse reactions are fatigue, decreased appetite, dyspnea, cough, nausea, musculoskeletal pain, and constipation.
FDA approves Genentech’s cancer immunotherapy Tecentriq (atezolizumab) for people with a specific type of metastatic lung cancer [news release]. South San Francisco, CA: Genentech October 18, 2016. http://www.businesswire.com/news/home/20161018006709/en/FDA-Approves-Genentech%E2%80%99s-Cancer-Immunotherapy-TECENTRIQ%C2%AE-Atezolizumab. Accessed October 26, 2016.
Tecentriq [package insert]. South San Francisco, CA: Genentech Inc 2016. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed October 26, 2016.